Free Newsletter
EU issues Erbitux, Cymbalta decisions
The EMEA's Committee for Medicinal Products for Human Use (CHMP) issued a number of recommendations this week. Many, such as Merck received good news, but Eli Lilly was not so lucky. Here's a brief roundup:
- GlaxoSmithKline received a positive recommendation to add a stronger version to its line-up of the over-the-counter obesity med, Alli (orlistat).
- The committee supported Roche's application to extend the indication of Pegasys in combination with ribavirin to the treatment of hepatitis C.
- The panel backed wider approval of Sepracor's Lunivia for insomnia.
- Celgene's Vidaza (azacitidine) received a position opinion for wider indication for the treatment of myelodysplastic syndromes and acute myeloid leukaemia in adults.
- Merck KGaA received a positive recommendation for the indication of Erbitux for head and neck cancer.
-
Eli Lilly and Boehringer Ingelheim's Cymbalta was given a negative rating for the treatment of fibromyalgia.
- check out the CHMP release for a complete list
Related Articles:
EMEA issues host of decisions
Study boosts Cymbalta's pain app
Erbitux, KRAS gene star at ASCO
Be the first to comment
More stories about Merck Kgaa GlaxoSmithKline EMEA Eli Lilly Boehringer Ingelheim EMEA approval Sepracor Roche
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


